BTIG Maintains Buy on Viridian Therapeutics, Raises Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Julian Harrison has maintained a Buy rating on Viridian Therapeutics and raised the price target from $46 to $56, indicating confidence in the company's future performance.
September 10, 2024 | 3:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Julian Harrison has maintained a Buy rating on Viridian Therapeutics and increased the price target from $46 to $56, suggesting a positive outlook for the company's stock.
The increase in the price target from $46 to $56 by BTIG indicates a strong positive sentiment from the analyst, which is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100